8-K: Aptevo Therapeutics Executes 1-for-18 Reverse Stock Split

Aptevo Therapeutics Inc. has completed a 1-for-18 reverse stock split, effective December 29, 2025, to consolidate its common stock.

Summary

• Aptevo Therapeutics Inc. (the Company) effected a 1-for-18 reverse stock split of its common stock.
• The reverse stock split became effective at 5:01 p.m. Eastern Time on December 29, 2025.
• Stockholders approved a range of reverse split ratios (1-for-6 to 1-for-22) on July 24, 2025, with the Board of Directors approving the 1-for-18 ratio on December 17, 2025.
• Every 18 shares of issued and outstanding common stock were automatically combined into one share, without any change in the $0.001 par value per share.
• Proportionate adjustments will be made to the per share exercise price and number of shares issuable upon exercise or vesting of outstanding stock options, restricted stock units, and warrants.
• No fractional shares will be issued to stockholders; instead, they will receive a cash payment in lieu thereof.
• Warrant holders who would otherwise be entitled to a fractional share upon exercise will have their entitlement rounded up to the next whole share.
• The reverse stock split affects all stockholders proportionately and does not alter any stockholder's percentage ownership, except for those receiving cash for fractional shares.
• The Company's common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis when the market opens on December 30, 2025.
• A new CUSIP number, 03835L702, has been assigned to the Company's common stock following the reverse stock split.

Sentiment

Score: 4

Explanation: While a reverse stock split can help meet exchange listing requirements and increase per-share price, it does not fundamentally change the company's valuation or business prospects and is often perceived with caution by the market as it may signal underlying challenges.

Positives

• The reverse stock split results in a higher per-share trading price for the common stock.

Negatives

• Stockholders who would otherwise be entitled to a fractional share will receive a cash payment, which may result in a slight reduction of their overall equity position in the company.
• The reverse stock split does not alter the company's fundamental valuation or market capitalization.

Risks

• The Company's ability to continue as a going concern.
• A deterioration in the Company's business or prospects.
• Further assessment of preliminary or interim data or different results from later clinical trials.
• Adverse events and unanticipated problems and adverse developments in clinical development, including unexpected safety issues observed during a clinical trial.
• Changes in regulatory, social, macroeconomic, and political conditions.

Future Outlook

The Company anticipates that proportionate adjustments will be made to the per share exercise price and number of shares issuable upon the exercise or vesting of all outstanding stock options, restricted stock units, and warrants. The number of shares reserved for issuance under equity compensation plans will also be reduced proportionately. The Company disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Management Comments

• Marvin L. White, President and Chief Executive Officer, signed the Form 8-K on behalf of Aptevo Therapeutics Inc.

Industry Context

Reverse stock splits are typically undertaken by companies to increase their per-share stock price, often to meet minimum bid price requirements for continued listing on major stock exchanges like Nasdaq. This action aims to make the stock more attractive to a broader range of investors and institutional funds, which may have policies against investing in 'penny stocks'.

Corporate Governance

Stakeholder Impact

• Shareholders will hold fewer shares at a proportionately higher price per share, with those holding fractional shares receiving cash.
• Holders of stock options, restricted stock units, and warrants will see proportionate adjustments to their exercise prices and the number of shares underlying their awards.
• The overall percentage ownership of stockholders remains unchanged, except for the impact of fractional share cash payments.

Next Steps

• Common stock will begin trading on The Nasdaq Capital Market on a split-adjusted basis on December 30, 2025.
• Processing of cash payments in lieu of fractional shares for stockholders.

Key Dates

Recommendation

A reverse stock split is a mechanical corporate action that consolidates shares and increases the per-share price without altering the company's underlying valuation or business fundamentals. While it may address exchange listing requirements, it often signals underlying challenges. Investors should hold and monitor future operational and financial performance rather than reacting solely to this structural change.

Keywords

Aptevo Therapeutics, Reverse Stock Split, APVO, Nasdaq, Corporate Action, Stock Consolidation, Certificate of Amendment